Table 2 Incidence and outcome of SARS-CoV-2 infection in persons with Cystic Fibrosis (pwCF), November 2019 to January 2021
References | Study design | Number of patients | Period(s) | Main findings |
|---|---|---|---|---|
Mathew HR, Choi MY, Parkins MD, Fritzler MJ. Systematic review: cystic fibrosis in the SARS-CoV-2/COVID-19 pandemic. BMC Pulm Med. 2021 May 20;21(1):173. https://0-doi-org.brum.beds.ac.uk/10.1186/s12890-021 [26] | Systematic review | 339 individuals with CF who developed COVID-19 | Between April 28 and December 10, 2020 | within the CF population, the post-transplantation, may experience a more severe clinical course COVID-19 |
Hadi YB et al. Outcomes of SARS-CoV-2 infection in patients with cystic fibrosis: a multicenter retrospective research network study. Respir Med. 2021 Nov;188:106,606. https://0-doi-org.brum.beds.ac.uk/10.1016/j.rmed.2021.106606 [27] | A multicenter retrospective research network study | A total of 507,810 patients with COVID-19 were included (422 patients, 0.08% with CF; 507,388 patients, 99.92% without CF. Mean age at COVID-19 diagnosis in CF cohort was 46.6 ± 19.3 years, with female predominance (n = 225, 53.32%) | Between January 20, 2020, and January 09, 2021 | In the crude, unmatched analysis, mortality, hospitalization, critical care need, mechanical ventilation, acute kidney injury and composite (combination of intubation and mortality) outcome at 30 days was higher in the pwCF |
Jung A et al. Factors for severe outcomes following SARS-CoV-2 infection in people with cystic fibrosis in Europe. ERJ Open Res. 2021 Dec 27;7(4):00411–2021. https://0-doi-org.brum.beds.ac.uk/10.1183/23120541.00411-2021 [28] | Observational study | 828 individuals with pwCF and SARS-CoV-2 infected | Between June 30, 2020 and December 31, 2020 | SARS-CoV-2 infection yielded high morbidity and hospitalisation in pwCF. PwCF with forced expiratory volume in 1 s < 70% predicted, CFRD and those with lung transplants are at particular risk of more severe outcomes |
McClenaghan E et al. The global impact of SARS-CoV-2 in 181 people with cystic fibrosis. J Cyst Fibros. 2020 Nov;19(6):868–871. https://0-doi-org.brum.beds.ac.uk/10.1016/j.jcf.2020.10.003 [29] | Observational study | 181 people with CF | All the studies published from the beginning of the first case of COVID-19 (17 November 2019) to 13 June 2020 | Infection with SARS-CoV-2 appears to exhibit a similar spectrum of outcomes to that seen in the general population, with 11 people admitted to intensive care (7 post-transplant), and 7 deaths (3 post-transplant). A more severe clinical course may be associated with older age, CF-related diabetes, lower lung function in the year prior to infection, and having received an organ transplant |